CAC
AUPH icon

Cowen and Company’s Aurinia Pharmaceuticals AUPH Stock Holding History

Cowen and Company’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,776
Closed -$265K – 598
2021
Q1 		$270K Buy
+20,776
New +$301K 0.02% 241

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Cowen and Company's AUPH Position: Q2 2021 in Review

Cowen and Company sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2021, closing a stake of 20,776 shares — an estimated $265K sold.

Cowen and Company first reported a position in AUPH in Q1 2021 and held it in 1 quarter. The position peaked at $270K in Q1 2021. 167 funds tracked by Wall St. Rank hold AUPH as of Q2 2021.

  • Cowen and Company reported no remaining Aurinia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Cowen and Company sold 20,776 Aurinia Pharmaceuticals shares in Q2 2021, an estimated $265K.
  • Cowen and Company first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Cowen and Company's Aurinia Pharmaceuticals position peaked at $270K in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.